Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Sticks To Script When Responding to Roche

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche’s next line will likely involve a sweeter offer.

You may also be interested in...



Genentech/Roche: The End Of An Era

Roche offers to buy out Genentech’s minority stakeholders for $89 per share, or $43.7 billion, to create the seventh largest U.S. pharma company.

Roche Finally Gets A Nod With $3.4 Billion Bid For Ventana

After seven months and a half dozen attempts to acquire the diagnostics company, Roche wins over Ventana’s board with a sweetened bid .

Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure

Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.

Topics

UsernamePublicRestriction

Register

PS068142

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel